Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 1 , Pages 9-20, January 2008

Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes

Dr. Correll is with The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, and the Albert Einstein College of Medicine

Accepted 6 September 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Assistant Editor's Note: Psychopharmacology Perspectives will bridge clinical and research expertise in pediatric psychopharmacology, with the goal of providing clinicians with practical clinical insights and up-to-date assessments of the evidence base. Authors will be invited to submit in-depth discussions of various topics in pediatric psychopharmacology, including experience-based practical guidance and the scientific rationale for treatment recommendations. Please feel free to contact me at ckratoch@unmc.edu if you have comments on this feature's revised format, or recommendations for future psychopharmacology topics of interest.

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

 Disclosure: Dr. Correll has been a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Intra-Cellular Therapeutics, Organon, Otsuka, Pfizer, Solvay, Supernus, and Vanda, and has served on the speakers' bureaus/advisory boards of AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, and Otsuka.

PII: S0890-8567(09)62080-3

doi:10.1097/chi.0b013e31815b5cb1

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 1 , Pages 9-20, January 2008

Article Tools